stemmacolore
Search

Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

Studio in aperto, a braccio singolo, di Fase Ib/IIa per valutare la sicurezza e l’efficacia dell’antagonista del recettore EP4 vorbipiprant (CR6086) in combinazione con l’inibitore di PD-1 balstilimab (AGEN2034), in pazienti affetti da carcinoma del colon- retto metastatico, con conservata capacità di riparazione del mismatch e stabilità dei microsatelliti già trattato in precedenza, e altri carcinomi gastrointestinali metastatici.

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
CR6086-1-04
Codice EudraCT
2024-515446-16-00
Sponsor/Promotore
Rottapharm Biotech S.r.l.
Tipologia
Sperimentale
Fase
I / II
Unità Operativa
Oncologia 1
Principal Investigator

Phase III randomized study of folfoxiri plus bevacizumab and atezolizumab versus folfoxiri plus bevacizumab as first-line treatment of unresectable pMMR and immunoscore IC-high metastatic colorectal cancer patients

Stato
Autorizzato - In attesa di apertura
Codice studio
AtezoTRIBE 2
Codice EudraCT
2023-506632-32-00
Sponsor/Promotore
GONO Gruppo Oncologico Nord Ovest
Tipologia
Sperimentale
Fase
III
Unità Operativa
UOS Sperimentazioni cliniche fasi precoci
Principal Investigator

Studio di fase II a singolo braccio di valutazione del ritrattamento guidato dal CT-DNA con encorafenib e cetuximab di pazienti con tumore del colon-retto metastatico BRAFV600E mutato

Stato
Aperto - reclutamento in corso
Codice studio
BRICKET
Codice EudraCT
2023-509088-26-00
Sponsor/Promotore
GONO Gruppo Oncologico Nord Ovest
Tipologia
Sperimentale
Fase
II
Unità Operativa
UOS Sperimentazioni cliniche fasi precoci
Principal Investigator

Studio multicentrico globale di fase III, randomizzato, in doppio cieco, controllato con placebo volto a valutare rilvegostomig in combinazione con chemioterapia come trattamento adiuvante in partecipanti adulti dopo resezione del tumore delle vie biliari con intento curativo (ARTEMIDE- Biliary01)

Stato
Aperto - reclutamento in corso
Codice studio
D7025C00001 (ARTEMIDE-Biliary01)
Codice EudraCT
2023-506054-20-00
Sponsor/Promotore
AstraZeneca AB
Tipologia
Sperimentale
Fase
III
Unità Operativa
UOS Sperimentazioni cliniche fasi precoci
Principal Investigator

Studio di fase III randomizzato per valutare l’efficacia e la sicurezza di Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + chemioterapia rispetto alla terapia standard come trattamento di prima linea in pazienti con carcinoma esofageo metastatico

Stato
Aperto - reclutamento in corso
Codice studio
MK7902-014 (LEAP-014)
Codice EudraCT
2022-501342-29
Sponsor/Promotore
Merck Sharp & Dohme corp
Tipologia
Sperimentale
Fase
III
Unità Operativa
UOS Sperimentazioni cliniche fasi precoci
Principal Investigator

Studio di Fase 3, in aperto, randomizzato con dostarlimab in monoterapia perioperatoria versus Standard of Care in partecipanti con carcinoma del colon resecabile T4N0 o Stadio III dMMR/MSI-H, non trattato

Stato
Aperto - reclutamento in corso
Codice studio
219606 (AZUR-2)
Codice EudraCT
2023-503265-27-00
Sponsor/Promotore
Glaxosmithkline
Tipologia
Sperimentale
Fase
III
Unità Operativa
UOS Sperimentazioni cliniche fasi precoci
Principal Investigator

Search

Status

Last modified: 06/04/2021 15:13

Scroll to Top